ClinicalTrials.gg
Active, not recruitingNCT05348577CAPItello280Updated Jan 27, 2025

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

A Phase 3 interventional study of capivasertib and docetaxel in Prostate Cancer, sponsored by AstraZeneca. Active, not recruiting at 217 sites in 22 countries. Open to male participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,035
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing capivasertib in Prostatic Neoplasms — 3 open to participants now, 6 under way, 3 of them phase 3. capivasertib · Prostatic Neoplasms.

Enrollment
2nd of 10
1,035 · median 238
Started
2022
the only one that year
Phase 3
3 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
4 of 10
AstraZeneca

Among the 10 studies testing capivasertib in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2022, is one of 3 in phase 3, and was the 9th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 10 studies testing capivasertib in Prostatic Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About capivasertib

capivasertib: first FDA approval 2023 (TRUQAP), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 130 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing capivasertib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.

03

Conditions studied

  • Prostate Cancer

Keywords

  • prostate cancer,
  • metastatic
  • castration resistant
  • capivasertib,
  • AKT inhibitor,
  • docetaxel
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -confirmed prostate adenocarcinoma without predominant neuroendocrine or small cell cancers
  • disease documented prior to randomisation by clear evidence of ≥ 1 bone lesion (defined as 1 lesion with positive uptake on bone scan) and/or ≥ 1 soft tissue lesion (measurable or non-measurable)
  • Patient must have been previously treated with a next generation hormonal agent (NHA), ie, abiraterone, enzalutamide, apalutamide or darolutamide, for prostate cancer for at least 3 months and shown evidence of disease progression (radiological or via PSA assessment) while receiving the NHA
  • Evidence of mCRPC with progression of disease despite androgen deprivation therapy (ADT)
  • Serum testosterone level ≤ 50 ng/dL
  • Candidate for docetaxel and therapy
  • Ongoing ADT with LHRH agonist, LHRH antagonist, or bilateral orchiectomy
  • (ECOG)/World Health Organisation (WHO) performance status 0 to 1 and anticipated minimum of 12 weeks
  • Confirmation that archival formalin-fixed paraffin-embedded (FFPE) tumour tissue sample which meets the minimum pathology and sample requirements is available to send to the central laboratory
  • Able and willing to swallow and retain oral medication
  • Agreement to remain abstinent (refrain from heterosexual intercourse) or use measures, and agreement to refrain from donating sperm

Exclusion criteria

Exclusion Criteria:

  • Radiotherapy with a wide field of radiation within 4 weeks before start of study treatment
  • Major surgery (excl. placement of vascular access, transurethral resection of prostate, bilateral orchiectomy, internal stents) within 4 weeks of start of study treatment
  • ,or spinal cord compression (unless spinal cord compression is asymptomatic and stable and not requiring for at least 4 weeks prior to start of study treatment)
  • Any of the following cardiac criteria:

    i. Mean resting interval (QTc) >470 msec from 3 consecutive ECGs ii. Any abnormalities in rhythm, conduction or morphology of resting iii. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age,or any concomitant medication known to prolong the QT interval iv. Experience of any of the following procedures or conditions in the preceding 3 months: coronary artery bypass graft, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure Grade ≥2 v. Symptomatic hypotension - systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<50 mmHg vi. haemodinamic instability

  • Clinically significant abnormalities of glucose metabolism as defined by any of the following:

    i. Patients with diabetes mellitus (DM) type 1 or DM type 2 requiring insulin treatment ii. ≥8.0% (63.9 mmol/mol)

  • Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

    i. \< 1.5x 10\^9/L ii. count \< 100x 10\^9/L iii. \< 9 g/dL (\< 5.59 mmol/L) iv. (ALT) and aspartate aminotransferase (AST) > 2.5x (ULN) if no demonstrable liver or > 5x ULN in the presence of liver metastases. Elevated alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone metastases and liver function is otherwise considered adequate in the investigator's judgement v. Total > 1.5x ULN (participants with confirmed Gilbert's syndrome may be included in the study with a higher value) vi. \< 50 mL/min per the Cockcroft and Gault formula without the need for chronic dialysis;

  • As judged by the investigator, any evidence of diseases (including severe or uncontrolled systemic diseases, uncontrolled hypertension, history of interstitial pneumonia / pneumonitis or interstitial lung disease, renal transplant and active bleeding diseases), which, in the investigator's opinion, makes it undesirable for the patient to participate in the study or that would jeopardise compliance with the protocol.
  • nausea and vomiting, malabsorption syndrome, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib
  • Any other disease, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contra-indicates the use of an drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining . Evidence of dementia, altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent.
  • Previous bone marrow transplant or solid organ transplant
  • History of another primary except for malignancy treated with curative intent with no known active disease ≥2 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin cancer and curatively treated in situ disease.
  • Persistent toxicities ( Grade ≥2) caused by previous anticancer therapy, excluding alopecia. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included (eg, hearing loss)
  • Known to have active hepatitis infection.
  • Known to have (HIV) with a detectable viral RNA load or a \< 350 cells/uL or a history of an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months, or receiving anti-HIV medications for less than 4 weeks.
  • Known to have active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
  • Treatment with any of the following:

    i. Prior chemotherapy for CRPC. Chemotherapy for metastatic or localized HSPC (including docetaxel) is allowed provided that chemotherapy was completed ≥ 6months before randomisation and progression of the prostate cancer occurred ≥ 6months after the completion of therapy.

ii. Prior exposure to AKT inhibitors or PI3K inhibitors iii. Any investigational agents or study drugs from a previous clinical study within 30 days or 5 half-lives (whichever is longer) of the first dose of study treatment iv. Any other immunotherapy, medication (other than corticosteroids) or anticancer agents (except ADT) within 3 weeks of the first dose of study treatment v. Strong inhibitors or strong inducers of cytochrome P450 (CYP)3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), vi.Use of any administration 30 days prior to the initiation of study treatment, during, and for at least 90 days after the last dose of the study treatment

  • Drugs known to significantly prolong the QT interval and associated with Torsade de Pointes within 5 half-lives of the first dose of study treatment
  • History of to active or inactive of capivasertib, docetaxel, or drugs with a similar chemical structure or class
  • Any restriction or based on the local prescribing information that would prohibit the use of docetaxel
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,035 participants (actual)

Study arms

  • Experimental
    capivasertib + docetaxel

    Participants receive capivasertib in combination with docetaxel and steroids on a background of ADT.

    Drug: capivasertib · Drug: docetaxel

  • Placebo comparator
    placebo + docetaxel

    Participants receive placebo in combination with docetaxel and steroids on a background of ADT.

    Drug: docetaxel · Other: placebo

Interventions

  • 320 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.

  • Patients will receive docetaxel in intravenous infusion, 75 mg/m2 BSA, on Day 1 of the 21-day cycles for up to 6 to 10 cycles, according to standard of care practices.

  • Otherplacebo

    matched to capivasertib appearance (2 tablets) BD given orally on an intermittent weekly dosing schedule. Patients will be dosed on Days 2 to 5, 9 to 12, and 16 to 19 in each week of a 21-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops, death, or if the patient requests to stop the study treatment.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in the overall population

    Overall survival is defined as time from randomisation until the date of death due to any cause.

    Time frame: up to approximately 46 months

  2. Radiographic Progression-free Survival (rPFS) in the overall population

    Radiographic Progression-free Survival (rPFS) is defined as time from randomization to radiographic progression as assessed by the investigator per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) for soft tissue and/or Prostate Cancer Working Group 3 (PCWG3) for bone or death due to any cause

    Time frame: up to approximately 37 months

Secondary outcomes

  1. Overall Survival (OS) in patients with mCRPC and PTEN-proficient tumours (IHC)

    OS is defined as time from randomisation until the date of death due to any cause.

    Time frame: up to approximately 46 months

  2. Overall Survival (OS) in patients with mCRPC and PTEN-deficient tumours (IHC).

    OS is defined as time from randomisation until the date of death due to any cause.

    Time frame: up to approximately 46 months

  3. Radiographic Progression-free Survival (rPFS) in patients with mCRPC and PTEN-proficient tumours (IHC)

    Radiographic progression-free survival is defined as the time from randomisation to radiographic progression, as assessed by the investigator at local site per RECIST version 1.1 (soft tissue) and/or PCWG3 criteria (bone), or death due to any cause.

    Time frame: up to approximately 37 months

  4. Radiographic Progression-free Survival (rPFS) in patients with mCRPC and PTEN-deficient tumours (IHC)

    Radiographic progression-free survival is defined as the time from randomisation to radiographic progression, as assessed by the investigator at local site per RECIST version 1.1 (soft tissue) and/or PCWG3 criteria (bone), or death due to any cause.

    Time frame: up to approximately 37 months

  5. Time to pain progression (TTPP) in the overall population

    Time to pain progression (TTPP) based on a 2-point increase from baseline in the Brief Pain Inventory-Short Form (BPI-SF) Item 3 'pain at its worse in the last 24 hours' score (scale from 0 \["no pain"\] to 10 \["pain as bad as you can imagine"\]) and/or initiation of/increase in opioid analgesic use.

    Time frame: up to approximately 37 months

  6. Time to first Symptomatic Skeletal-Related Event (SSRE) in the overall population

    SSRE is defined as time from randomisation until any of the following: use of radiation therapy to prevent or relieve skeletal symptoms; Occurrence of new symptomatic pathological bone fractures; Occurrence of spinal cord compression; Orthopaedic surgical intervention for bone metastasis

    Time frame: up to approximately 46 months

  7. Time to deterioration in urinary symptoms (TTDUS) in the overall population

    Time to deterioration in urinary symptoms (TTDUS) is defined as time from randomization until the change from baseline reaches a clinically meaningful deterioration threshold using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Prostate Questionnaire Urinary Symptoms (QLQ-PR25 (US)) subscale score (EORTC IL166), where the question responses are provided on a numerical rating scale ranging from 1 ("not at all") to 4 ("very much").

    Time frame: up to approximately 37 months

  8. Time to deterioration in Physical Functioning (TTDPF) in the overall population

    Time to deterioration in Physical Functioning (TTDPF) is defined as the time from randomization until the change from baseline reaches a clinically meaningful deterioration threshold using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Physical Functioning (QLQ-C30 PF) subscale score (EORTC IL166), where the question responses are provided on a numerical rating scale ranging from 1 ("not at all") to 4 ("very much").

    Time frame: up to approximately 37 months

  9. Overall Pain Severity and Pain Interference as assessed by BPI-SF questionnaire in the overall population

    Change from baseline in Brief Pain Inventory-Short Form (BPI-SF) pain at its worse in the last 24 hours score (scale from 0 \["no pain"\] to 10 \["pain as bad as you can imagine"\]), pain severity (the mean of the four pain severity items each of which ranges from 0 \["no pain"\] to 10 \["pain as bad as you can imagine"\]) and interference domain scores (the mean of the seven pain interference items each of which ranges from 0 \["does not interfere"\] to 10 \["completely interferes"\]).

    Time frame: up to approximately 37 months

  10. Plasma concentration of capivasertib derived from a population PK model in the overall population

    Time frame: pre dose (up to 90 minutes prior) and post dose (1 hour, 2 hours and 4 hours post dose)

Other outcomes

  1. The number of participants with adverse events in the overall population

    Data will include clinical observations, ECG parameters, clinical chemistry / haematology / glucose metabolism parameters and vital signs assessed as the number of participants with adverse events.

    Time frame: Up to approximately 46 months

  2. Systolic and diastolic blood pressure

    millimetre of mercury (mmHg)

    Time frame: Up to approximately 46 months

  3. Pulse rate (heart rate)

    Beats per minute (BPM)

    Time frame: Up to approximately 46 months

  4. Body Temperature

    Celsius (°C)

    Time frame: Up to approximately 46 months

  5. Weight

    Kilograms (kg)

    Time frame: Up to approximately 46 months

07

Study locations

217 sites
  • Research Site
    Yuma, Arizona 85364, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Cerritos, California 90703, United States
  • Research Site
    Fresno, California 93701, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Sacramento, California 95817, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    Santa Barbara, California 93105, United States
  • Research Site
    Santa Monica, California 90404, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Lakewood, Colorado 80228, United States
  • Research Site
    Littleton, Colorado 80120, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Minneapolis, Minnesota 55404, United States
  • Research Site
    Minneapolis, Minnesota 55416, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    White Plains, New York 10601, United States
  • Research Site
    Toledo, Ohio 43623, United States
  • Research Site
    Portland, Oregon 97223, United States
  • Research Site
    Bala-Cynwyd, Pennsylvania 19004-1017, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Watertown, South Dakota 57201, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Austin, Texas 78731, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Houston, Texas 77096, United States
  • Research Site
    Kingwood, Texas 77339, United States
  • Research Site
    San Antonio, Texas 78217, United States
  • Research Site
    Chesapeake, Virginia 23320, United States
  • Research Site
    Seattle, Washington 98109, United States
  • Research Site
    Birtinya, 4575, Australia
  • Research Site
    Greenslopes, 4120, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    North Adelaide, 5000, Australia
  • Research Site
    Orange, 2800, Australia
  • Research Site
    Redcliffe, 4020, Australia
  • Research Site
    Wahroonga, 2076, Australia
  • Research Site
    Brasschaat, 2930, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Cachoeiro de Itapemirim, 29308-014, Brazil
  • Research Site
    Ijuí, 98700-000, Brazil
  • Research Site
    Itajai, 88301-220, Brazil
  • Research Site
    Joinville, 89201-470, Brazil
  • Research Site
    Porto Alegre, 90020-090, Brazil
  • Research Site
    Porto Alegre, 90035-903, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Porto Alegre, 90160-093, Brazil
  • Research Site
    Recife, 50040-000, Brazil
  • Research Site
    Rio de Janeiro, 22281-100, Brazil
  • Research Site
    Rio De Janeiro, 22793-080, Brazil
  • Research Site
    Salvador, 41253-190, Brazil
  • Research Site
    Salvador, 41820-021, Brazil
  • Research Site
    Santa Maria, 97015-450, Brazil
  • Research Site
    Sao Paulo, 01509-900, Brazil
  • Research Site
    São José Do Rio Preto - SP, 15090-000, Brazil
  • Research Site
    São Paulo, 01221-020, Brazil
  • Research Site
    São Paulo, 04014-002, Brazil
  • Research Site
    Tres Lagoas, 79601-001, Brazil
  • Research Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Toronto, M4N 3M5, Canada
  • Research Site
    Santiago, 7500713, Chile
  • Research Site
    Santiago, 7500918, Chile
  • Research Site
    Santiago, 7650568, Chile
  • Research Site
    Vina del Mar, 2520000, Chile
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100034, China
  • Research Site
    Beijing, 100050, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Guangzhou, 510180, China
  • Research Site
    Hangzhou, 310000, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Harbin, 150040, China
  • Research Site
    Jiaxing, 314001, China
  • Research Site
    Nanchang, 330019, China
  • Research Site
    Nanjing, 210008, China
  • Research Site
    Nantong, 226361, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Tianjin, 300052, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Yantai, 264000, China

Showing the first 100 of 217 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Mar 2026, 47 months after the start.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's planned 47 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2022
First posted
Apr 27, 2022
StartActual
Mar 25, 2022
Primary completionEst.
Mar 4, 2026
CompletionEst.
Mar 4, 2026
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05348577
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Mar 25, 2022
Primary completion
Mar 4, 2026 (estimated)
Completion
Mar 4, 2026 (estimated)
Last update
Jan 27, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capivasertib

Start the discussion